Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial.

Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, González C, Ercole L, Alonso R, Fonseca JE; ToSpace Study group.

Arthritis Rheumatol. 2019 Apr 5. doi: 10.1002/art.40905. [Epub ahead of print]

PMID:
31087542
2.

Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.

Pablos JL, Navarro F, Blanco FJ, Román-Ivorra JA, Alonso A, Martín Mola E, Cantalejo M, Ercole L, Rivero N; study investigators.

Clin Exp Rheumatol. 2019 May-Jun;37(3):437-444. Epub 2018 Sep 17.

3.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

4.

Color Doppler and spectral Doppler ultrasound detection of active sacroiliitis in spondyloarthritis compared to physical examination as gold standard.

Castillo-Gallego C, De Miguel E, García-Arias M, Plasencia C, Lojo-Oliveira L, Martín-Mola E.

Rheumatol Int. 2017 Dec;37(12):2043-2047. doi: 10.1007/s00296-017-3813-3. Epub 2017 Sep 13.

PMID:
28905097
5.

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study.

Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, Ruiz-Esquide V, Corrales A, Narváez J, Rey-Rey J, Rodríguez-Lozano C, Ojeda S, Muñoz-Fernández S, Nolla JM, García-Torrón J, Gamero F, García-Vicuña R, Hernández-Cruz B, Campos J, Rosas J, García-Llorente JF, Gómez-Centeno A, Cáliz R, Sanmartí R, Bermúdez A, Abasolo-Alcázar L, Fernández-Nebro A, Rodríguez-Rodríguez L, Marras C, González-Gay MÁ, Hmamouchi I, Martín-Mola E.

Reumatol Clin. 2019 Mar - Apr;15(2):102-108. doi: 10.1016/j.reuma.2017.06.002. Epub 2017 Jul 12. English, Spanish.

6.

Increased frequency of circulating CD19+CD24hiCD38hi B cells with regulatory capacity in patients with Ankylosing spondylitis (AS) naïve for biological agents.

Bautista-Caro MB, de Miguel E, Peiteado D, Plasencia-Rodríguez C, Villalba A, Monjo-Henry I, Puig-Kröger A, Sánchez-Mateos P, Martín-Mola E, Miranda-Carús ME.

PLoS One. 2017 Jul 6;12(7):e0180726. doi: 10.1371/journal.pone.0180726. eCollection 2017.

7.

Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment.

Peiteado D, Villalba A, Martín-Mola E, Balsa A, De Miguel E.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):746-751. Epub 2017 Mar 3.

PMID:
28281462
8.

Adaptation of the osteoarthritis-specific quality of life scale (the OAQoL) for use in Germany, Hungary, Italy, Spain and Turkey.

Wilburn J, McKenna SP, Kutlay Ş, Bender T, Braun J, Castillo-Gallego C, Favero M, Geher P, Kiltz U, Martin-Mola E, Ramonda R, Rouse M, Tennant A, Küçükdeveci AA.

Rheumatol Int. 2017 May;37(5):727-734. doi: 10.1007/s00296-017-3664-y. Epub 2017 Feb 15.

PMID:
28197718
9.

Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain.

Nolla JM, Rodríguez M, Martin-Mola E, Raya E, Ibero I, Nocea G, Aragon B, Lizán L, Prades M.

Patient Prefer Adherence. 2016 Jun 20;10:1101-13. doi: 10.2147/PPA.S106311. eCollection 2016.

10.

The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis.

Kviatkovsky MJ, Ramiro S, Landewé R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaud P, Martin-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D.

J Rheumatol. 2016 Sep;43(9):1680-6. doi: 10.3899/jrheum.151244. Epub 2016 Jun 15.

PMID:
27307522
11.

Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Martin-Mola E, Balsa A, García-Vicuna R, Gómez-Reino J, González-Gay MA, Sanmartí R, Loza E.

Rheumatol Int. 2016 Aug;36(8):1043-63. doi: 10.1007/s00296-016-3506-3. Epub 2016 Jun 6. Review.

PMID:
27271502
12.

Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19.

PMID:
27214767
13.

Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review.

Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Balsa A, Martín-Mola E, Seoane-Mato D, Cañete JD.

Rheumatology (Oxford). 2016 Jul;55(7):1188-94. doi: 10.1093/rheumatology/kew033. Epub 2016 Mar 21. Review.

PMID:
26998860
14.

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

Plasencia C, Jurado T, Villalba A, Peitedado D, Casla MT, Nuño L, Bonilla MG, Martínez-Feito A, Martín-Mola E, Pascual-Salcedo D, Balsa A.

Front Med (Lausanne). 2015 Oct 8;2:71. doi: 10.3389/fmed.2015.00071. eCollection 2015.

15.

Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database.

Gvozdenović E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landewé RB.

J Clin Rheumatol. 2015 Oct;21(7):349-54. doi: 10.1097/RHU.0000000000000296.

PMID:
26398461
16.

Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D.

J Rheumatol. 2015 Sep;42(9):1638-46. doi: 10.3899/jrheum.141128. Epub 2015 Jul 15.

PMID:
26178279
17.

Evolution in the use of musculoskeletal ultrasonography in a Rheumatology Unit over 14 years.

Gil Barato S, de Miguel Mendieta E, Martin-Mola E.

Reumatismo. 2015 Jun 30;67(1):8-12. doi: 10.4081/reumatismo.2015.792.

18.

Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.

Baron R, Likar R, Martin-Mola E, Blanco FJ, Kennes L, Müller M, Falke D, Steigerwald I.

Pain Pract. 2016 Jun;16(5):580-99. doi: 10.1111/papr.12308. Epub 2015 Jun 12.

PMID:
26095455
19.

2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.

Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, Fernández-Nebro A, Ferraz-Amaro I, Gómez-Reino JJ, González-Álvaro I, Martín-Mola E, Martínez-Taboada VM, Ortiz AM, Tornero J, Marsal S, Moreno-Muelas JV.

Reumatol Clin. 2015 Sep-Oct;11(5):279-94. doi: 10.1016/j.reuma.2015.05.001. Epub 2015 Jun 6. English, Spanish.

20.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12. Review.

21.

Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment?

Peiteado D, Villalba A, Martín-Mola E, de Miguel E.

Clin Exp Rheumatol. 2015 May-Jun;33(3):385-90. Epub 2015 Apr 16.

PMID:
25898174
22.

Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis.

Bellamy N, Hochberg M, Tubach F, Martin-Mola E, Awada H, Bombardier C, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D, Dougados M.

Arthritis Care Res (Hoboken). 2015 Jul;67(7):972-80. doi: 10.1002/acr.22538.

23.

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Román Ivorra JA, Poveda-Andrés JL, Muñoz-Fernández S; Spanish Rheumatology Society; Spanish Rheumatology Society.

Rheumatology (Oxford). 2015 Jul;54(7):1200-9. doi: 10.1093/rheumatology/keu461. Epub 2014 Dec 19.

24.

Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in rheumatoid arthritis.

Arroyo-Villa I, Bautista-Caro MB, Balsa A, Aguado-Acín P, Bonilla-Hernán MG, Plasencia C, Villalba A, Nuño L, Puig-Kröger A, Martín-Mola E, Miranda-Carús ME.

Arthritis Res Ther. 2014 Dec 5;16(6):500. doi: 10.1186/s13075-014-0500-6.

25.

Sustained remission with etanercept tapering in early rheumatoid arthritis.

Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, Krogulec M, Williams T, Gaylord S, Pedersen R, Bukowski J, Vlahos B.

N Engl J Med. 2014 Nov 6;371(19):1781-92. doi: 10.1056/NEJMoa1316133.

26.

Can we use enthesis ultrasound as an outcome measure of disease activity in spondyloarthritis? A study at the Achilles level.

Falcao S, Castillo-Gallego C, Peiteado D, Branco J, Martín Mola E, de Miguel E.

Rheumatology (Oxford). 2015 Sep;54(9):1557-62. doi: 10.1093/rheumatology/keu399. Epub 2014 Oct 8.

PMID:
25296747
27.

Decreased frequencies of circulating follicular helper T cell counterparts and plasmablasts in ankylosing spondylitis patients Naïve for TNF blockers.

Bautista-Caro MB, Arroyo-Villa I, Castillo-Gallego C, de Miguel E, Peiteado D, Plasencia-Rodríguez C, Villalba A, Sánchez-Mateos P, Puig-Kröger A, Martín-Mola E, Miranda-Carús ME.

PLoS One. 2014 Sep 9;9(9):e107086. doi: 10.1371/journal.pone.0107086. eCollection 2014.

28.

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.

Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M.

Ann Rheum Dis. 2015 Jan;74(1):35-43. doi: 10.1136/annrheumdis-2014-205752. Epub 2014 Aug 28.

29.

IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.

Tanaka Y, Martin Mola E.

Ann Rheum Dis. 2014 Sep;73(9):1595-7. doi: 10.1136/annrheumdis-2013-205002. Epub 2014 May 15. No abstract available.

PMID:
24833786
30.
31.

Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.

Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J.

Ann Intern Med. 2013 Aug 20;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006.

PMID:
24026258
32.

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, Peiteado D, Arribas F, Díez J, López-Casla MT, Martín-Mola E, Balsa A.

Arthritis Res Ther. 2013 Jul 26;15(4):R79. doi: 10.1186/ar4258.

33.

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.

Farahmand P, Marin F, Hawkins F, Möricke R, Ringe JD, Glüer CC, Papaioannou N, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Peña J, Graeff C, Kapetanos G, Petto H, Gentzel A, Reisinger A, Zysset PK.

Osteoporos Int. 2013 Dec;24(12):2971-81. doi: 10.1007/s00198-013-2379-5. Epub 2013 Jun 6.

34.

The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.

Plasencia Ch, Pascual-Salcedo D, Alcocer P, Bonilla MG, Villalba A, Peiteado D, Arribas F, Díez J, Lopez-Casla MT, Martín-Mola E, Balsa A.

Ann Rheum Dis. 2013 Nov;72(11):1888-90. doi: 10.1136/annrheumdis-2013-203353. Epub 2013 Jun 5. No abstract available.

PMID:
23740237
35.

Achilles enthesis ultrasound: the importance of the bursa in spondyloarthritis.

Falcao S, de Miguel E, Castillo-Gallego C, Peiteado D, Branco J, Martín Mola E.

Clin Exp Rheumatol. 2013 May-Jun;31(3):422-7. Epub 2013 Mar 7.

PMID:
23464885
36.

Doppler ultrasound--a valid and reliable tool to assess spondyloarthritis.

Falcão S, De Miguel E, Castillo C, Branco JC, Martín-Mola E.

Acta Reumatol Port. 2012 Jul-Sep;37(3):212-7. Review.

PMID:
23348109
37.

Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.

García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, Martín-Mola E, Balsa A.

Mol Diagn Ther. 2013 Feb;17(1):49-56. doi: 10.1007/s40291-013-0016-9.

PMID:
23329363
38.

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.

Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK.

J Bone Miner Res. 2013 Jun;28(6):1355-68. doi: 10.1002/jbmr.1870.

39.

The role of biosimilars in the treatment of rheumatic diseases.

Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR.

Ann Rheum Dis. 2013 Mar;72(3):322-8. doi: 10.1136/annrheumdis-2012-202715. Epub 2012 Dec 19. Review.

PMID:
23253920
40.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

41.

Decreased Th17 and Th1 cells in the peripheral blood of patients with early non-radiographic axial spondyloarthritis: a marker of disease activity in HLA-B27⁺ patients.

Bautista-Caro MB, Arroyo-Villa I, Castillo-Gallego C, de Miguel E, Peiteado D, Puig-Kröger A, Martín-Mola E, Miranda-Carús ME.

Rheumatology (Oxford). 2013 Feb;52(2):352-62. doi: 10.1093/rheumatology/kes267. Epub 2012 Oct 11.

PMID:
23065314
42.

Value of a short four-joint ultrasound test for gout diagnosis: a pilot study.

Peiteado D, De Miguel E, Villalba A, Ordóñez MC, Castillo C, Martín-Mola E.

Clin Exp Rheumatol. 2012 Nov-Dec;30(6):830-7. Epub 2012 Dec 17.

PMID:
23020889
43.

Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity.

Arroyo-Villa I, Bautista-Caro MB, Balsa A, Aguado-Acín P, Nuño L, Bonilla-Hernán MG, Puig-Kröger A, Martín-Mola E, Miranda-Carús ME.

PLoS One. 2012;7(8):e42189. doi: 10.1371/journal.pone.0042189. Epub 2012 Aug 3.

44.

IL-15 expression on RA synovial fibroblasts promotes B cell survival.

Benito-Miguel M, García-Carmona Y, Balsa A, Bautista-Caro MB, Arroyo-Villa I, Cobo-Ibáñez T, Bonilla-Hernán MG, Pérez de Ayala C, Sánchez-Mateos P, Martín-Mola E, Miranda-Carús ME.

PLoS One. 2012;7(7):e40620. doi: 10.1371/journal.pone.0040620. Epub 2012 Jul 9.

45.

Abatacept use in rheumatoid arthritis: evidence review and recommendations.

Martín Mola E, Balsa A, Martínez Taboada V, Sanmartí R, Marenco JL, Navarro Sarabia F, Gómez-Reino J, Alvaro-Gracia JM, Román Ivorra JA, Lojo L, Plasencia C, Carmona L; Spanish expert panel of rheumatologists.

Reumatol Clin. 2013 Jan-Feb;9(1):5-17. doi: 10.1016/j.reuma.2012.05.001. Epub 2012 Jul 4. English, Spanish.

46.

Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study.

Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, Felson DT, Hajjaj-Hassouni N, Hochberg M, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D, Dougados M.

Arthritis Care Res (Hoboken). 2012 Nov;64(11):1699-707. doi: 10.1002/acr.21747.

47.

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, Díez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A.

Ann Rheum Dis. 2012 Dec;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828. Epub 2012 May 6.

PMID:
22563028
48.

The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis.

De Miguel E, Roxo A, Castillo C, Peiteado D, Villalba A, Martín-Mola E.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S34-8. Epub 2012 May 10.

PMID:
22410311
49.

Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study.

De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martín-Mola E.

Ann Rheum Dis. 2012 Jan;71(1):157-8. doi: 10.1136/ard.2011.154997. Epub 2011 Sep 27. No abstract available.

PMID:
21953340
50.

[Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].

Hernández-Cruz B, García-Arias M, Ariza Ariza R, Martín Mola E.

Reumatol Clin. 2011 Sep-Oct;7(5):314-22. doi: 10.1016/j.reuma.2011.03.004. Epub 2011 Aug 2. Review. Spanish.

Supplemental Content

Loading ...
Support Center